Article thumbnail

Association of Serum Phosphate and Related Factors in ESRD-Related Vascular Calcification

By Cai-Mei Zheng, Kuo-Cheng Lu, Chia-Chao Wu, Yung-Ho Hsu and Yuh-Feng Lin


Vascular calcification is common in ESRD patients and is important in increasing mortality from cardiovascular complications in these patients. Hyperphosphatemia related to chronic kidney disease is increasingly known as major stimulus for vascular calcification. Hyperphosphatemia and vascular calcification become popular discussion among nephrologist environment more than five decades, and many researches have been evolved. Risk factors for calcification are nowadays focused for the therapeutic prevention of vascular calcification with the hope of reducing cardiovascular complications

Topics: Review Article
Publisher: SAGE-Hindawi Access to Research
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2010). A .C a u d r i l l i e r ,R .M e n t a v e r r i ,M .B r a z i e r ,S .K a m e l ,a n dZ
  2. (2005). A .J .B l e y e r ,J .B u r k a r t ,M .P i a z z a ,G .R u s s e l l
  3. (2007). A new approach to the evaluation of hyperphosphatemia in chronic kidney disease,”
  4. (2001). Acute correction of metabolic acidosis increases serum procollagen type I carboxyterminal propeptide in patients with chronic renal failure,”
  5. (2002). Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure,”
  6. (2003). An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis,”
  7. (1992). Arterial calcinosis, chronic renal failure and calcium antagonism,”
  8. (2000). Arterial stiffening and vascular calcifications in end-stage renal disease,”
  9. (2010). Bisphosphonate use and prevalence of valvular and vascular calcification in women
  10. (2009). Bisphosphonates and atherosclerosis,”
  11. (2005). Bisphosphonates may inhibit development of atherosclerosis formation through its bactericidal effect on nanobacteria,”
  12. (1991). Boneinducing activity of mature BMP-2b produced from a hybrid BMP-2a/2b precursor,”
  13. (2010). Boulanouar et al., “Implication of the calcium sensing receptor and the Phosphoinositide 3-kinase/Akt pathway in the extracellular calcium-mediated migration of RAW 264.7 osteoclast precursor cells,”
  14. (2004). C i c o n e ,J .B .P e t r o n i s ,C .D .E m b e r t ,a n dD .A .S p e c -tor, “Successful treatment of calciphylaxis with intravenous sodium thiosulfate,”
  15. (2009). Calcific uremic arteriolopathy (calciphylaxis): successful treatment with sodium thiosulfate in spite of elevated serum phosphate,”
  16. (2011). Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism,”
  17. (1984). Can biological calcification occur in the presence of pyrophosphate?”
  18. (2006). Cardiac vascular calcificationandQTintervalinESRDpatients:istherealink?”
  19. (2011). Cellular ATP synthesis mediated by type III sodium-dependent phosphate transporter Pit-1 is critical to chondrogenesis,”
  20. (2006). Chemical and hormonal determinants of vascular calcification in vitro,”
  21. (2003). Correlation of serum leptin concentrations with body composition and gender in taiwanese hemodialysis patients without diabetes,”
  22. (1994). Diang et al., “Influence of rapid correction of metabolic acidosis on serum osteocalcin level in chronicrenalfailure,”ASAIOJournal,vol.40,no.3,pp.M440– M444,
  23. (2008). Different risk factors for vascular calcification in end-stage renal disease betweendiabeticsandnondiabetics:therespectiveimportance of glycemic and phosphate control,”
  24. (1969). Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo,”
  25. (2009). Effect of leptin on vascular calcification
  26. (2008). Effects of calcimimetics on extraskeletal calcifications in chronic kidney disease,”
  27. (2005). Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis,”
  28. (2010). Efficacy and safety of SBR759, a new iron-based phosphate binder,”
  29. (2007). Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells,”
  30. (2009). Facta et al., “Improvement in coronary endothelial function is independently associated with a slowed progression of coronary artery calcification in type 2 diabetes mellitus,”
  31. (2010). Fetuin-A, osteoporosis and inflammation-proposal of possible mechanisms for vascular and valvular calcification in chronic kidney disease,”
  32. (2007). Fibroblast growth factor 23(FGF23)predictsprogressionofchronickidneydisease:the Mild to Moderate Kidney Disease (MMKD) study,”
  33. (2001). Futterweit et al., “American Association of Clinical Endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders,”
  34. (1997). G.Luo,P.Ducy,M.D.McKeeetal.,“Spontaneouscalcification of arteries and cartilage in mice lacking matrix
  35. (2008). G.Molostvov,S.Fletcher,R.Bland,andD.Zehnder,“Extracellular calcium-sensing receptor mediated signalling is involved in human vascular smooth muscle cell proliferation and apoptosis,”
  36. (2004). H.H.T.HsuandB.G.Abbo,“Roleofbicarbonate/CO2buffer in the initiation of vesicle-mediated calcification: mechanisms of aortic calcification related to atherosclerosis,”
  37. (2011). How KDIGO will (or will not) influence the management of hyperphosphatemia,”
  38. (2011). Hyodo et al., “Effect of sevelamer and calcium-basedphosphatebindersoncoronaryarterycalcification and accumulation of circulating advanced glycation end productsinhemodialysispatients,”AmericanJournalofKidney Diseases,
  39. (2011). Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mousesmoothmusclecellsinvitro,”
  40. (2010). Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial,”
  41. Improving bone formation in a rat femur segmental defect by controlling BMP-2 release,” Tissue Engineering Part A. In press.
  42. (1995). Influence of metabolic acidosis on serum
  43. (2007). Inhibitors of calcification in blood and urine,”
  44. (1981). Interference of nucleoside diphosphates and inorganic phosphate with nucleosidetriphosphate-dependent calcium fluxes and calciumdependent nucleoside-triphosphate hydrolysis in membranes of sarcoplasmic-reticulum vesicles,”
  45. (2004). Intestinal Na-P cotransporter adaptation to dietary P(i) content in vitamin D receptor null mice,”
  46. (2011). Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders,”
  47. Leptin Resistance. A possibleinterfaceof inflammation andmetabolism in obesityrelated cardiovascular disease,”
  48. Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure,” Nephrology Dialysis Transplantation.
  49. (2011). Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification,”
  50. (2004). Mechanism and therapy of vascular calcification,”
  51. (2008). Metabolic acidosis and vascular calcification: using blueprints from bone to map a new venue for vascular research,”
  52. (2008). Metabolic acidosis inhibits soft tissue calcification in uremic rats,”
  53. (2004). Mineral metabolism, mortality, and morbidity in maintenance hemodialysis,”
  54. (2011). Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo,”
  55. (1976). Modeling nucleus pulposus regeneration in vitro: mesenchymal stem cells, alginate beads, hypoxia, BMP-2, and synthetic peptide B2A,” Spine (Phila Pa
  56. (2010). Molecular mechanisms of vascular calcification,”
  57. (2000). Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure (multiple letters) [4],”
  58. (2000). Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure,”
  59. (2007). Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients,”
  60. (2011). o o r d z i j ,E .M .C r a n e n b u r g ,L .F .E n g e l s m a ne ta l . , “Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients,”
  61. (1986). Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans,”
  62. (2011). Overexpression of osteoprotegerin promotes preosteoblast differentiation to mature osteoblasts,”
  63. (2010). Overexpression of parathyroid pituitary-specific transcription factor (Pit)-1 in hyperphosphatemia-induced hyperparathyroidism of chronic renal failure rats,”
  64. (2010). P r o s d o c i m o ,S .C .W y l e r ,A .M .R o m a n i
  65. (2011). Phosphate and FGF-23,”
  66. (1989). Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men,”
  67. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?”
  68. (2011). Prevention of vascular calcification: is pyrophosphate therapy a solution?”
  69. (2005). Relation between serum phosphate level and cardiovascular event rate in people with coronary disease,”
  70. (2007). Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy,”
  71. (2005). Risk factors and underlying cardiovascular diseases in incident ESRD patients,”
  72. (2011). Role of calciumphosphate deposition in vascular smooth muscle cell calcification,”AmericanJournalofPhysiology,vol.300,no.1,pp.C210– C220,
  73. (2009). Salivary phosphatebinding chewing gum reduces hyperphosphatemia in dialysis patients,”
  74. (2005). Serum phosphate levels and mortality risk among people with chronic kidney disease,”
  75. (2009). Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation,”
  76. (2002). Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients,”
  77. (2010). Sharaf El Din, “Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients,”
  78. (2004). Skepper et al., “Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in
  79. (1986). The effect of oral phosphate administration on major indices of skeletal metabolism in normal subjects,”
  80. (2009). The survival advantage for haemodialysis patients taking vitamin D is questioned:
  81. (2009). To facilitate the compliance of phosphate binder for the control of hyperphosphatemia in chronic kidney disease patients,”
  82. (2008). Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data,”
  83. (2011). Treatment with pyrophosphate inhibits uremic vascular calcification,”
  84. (1998). ulbert-Shearon,N.W .Levin,andF .K.P ort, “Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study,”
  85. (2009). Vascular calcification and ESRD: a hard target,”
  86. (2009). Vascular calcification and metabolic acidosis in end stage renal disease,”
  87. (2011). Vascular calcification in chronic renal failure: what have we learned from animal studies?”
  88. (2004). Vascular calcification in ESRD: another cloud appears in the perfect storm—but highlights a silver lining?”
  89. (2004). Vascular calcification mechanisms,”
  90. (2004). Vascular calcification: mechanisms and clinical ramifications,”